Home
Search results “Preoperative radiation for rectal cancer”
Radiotherapy for Rectal Cancer, How Does it Work: Dr  Jeff Olsen
 
21:48
Dr. Jeffrey Olsen of Washington University discusses radiation therapy for rectal cancer and what to expect at SNMMI's 2014 Annual Meeting in St. Louis, Missouri.
Views: 8025 SNMChannel1
Challenges in the neoadjuvant radiation of rectal cancer by R. Glynne-Johns
 
03:24
Preoperative chemoradiation (CRT) has been the standard of care for all patients with clinical stage II and III rectal cancer; this is due to benefits such as a low rate of local recurrence, acceptable toxicity, potential sphincter preservation and potential organ preservation. Some heterogeneous data are currently available that must be analyzed carefully to obtain the best results for the patients. This is an excerpt from AISChannel.com. To watch the full video go here: http://aischannel.com/society/challenges-in-the-neoadjuvant-radiation-of-rectal-cancer/
Views: 177 AIS Channel
Preoperative chemoradiotherapy in rectal cancer
 
00:15
Preoperative chemoradiotherapy in rectal cancer significantly decreased local failure (6% vs 13%; P = .006) and sphincter preservation in low-lying tumors (39% vs 19%; P < .004).
Role of Imaging in Rectal Cancer by Dr. Anita Nagadi
 
05:52
Colorectal cancer is among the top 5 cancers worldwide. The objective of rectal imaging in rectal cancer is to help doctors distinguish patients who could benefit from preoperative chemo radiation compared to those who benefit from surgery alone. Dr. Anita Nagadi talks about rectal imaging technique, MRI sequence, and role of MRI in prognosis & post-surgery.
Views: 37 Happidoc Social
Advantages of Transperineal Approach for Rectal Cancer following Radiotherapy to Prostate Cancer
 
08:18
This video edit shows the performance of a combined laparoscopic and transperineal approach for a patient who developed rectal cancer after receiving radiotherapy for prostate cancer. It is associated with a text under submission for publication in the journal Colorectal Disease. Click Subscribe to this channel for the most up to date content. Authors: Kenji Kawada*, Koya Hida, Yoshiharu Sakai. Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. * Corresponding author: Kenji Kawada, MD, PhD. Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin- Kawara-cho, Sakyo-ku, Kyoto, Japan, 606-8507, Phone: +81-75-366-7595 FAX: +81-75-366-7642 E-mail: kkawada@kuhp.kyoto-u.ac.jp Video associated with Colorectal Disease Journal (published by Wiley and associated with the Association of Coloproctology Great Britain and Ireland (ACPGBI), European Society of Coloproctology (ESCP) and Spanish Society of Coloproctology (SSC).
Debate: Optimal neoadjuvant strategy in pancreatic cancer - Preoperative chemotherapy + radiation
 
10:52
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that preoperative chemotherapy plus radiation is the optimal neoadjuvant strategy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GDUGI © 2017 Imedex, LLC.
Views: 378 ImedexCME
Which neoadjuvant treatment in rectal cancer?
 
16:36
This Congress is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors. It has been endorsed by leading professional societies and organizations. With the focus on personalized therapy, multidisciplinary management and unraveling molecular mechanisms, the World Congress will educate and update the broad range of experts who participate in the treatment of gastrointestinal cancers, providing a clear overview for treatment. In this presentation, Dr. In this presentation, Dr. David Sebag-Montefiore discusses which neoadjuvant treatments should be used in rectal cancer, and for whom. © 2015 Imedex, LLC.
Views: 635 ImedexCME
Which neoadjuvant chemoradiotherapy regimen in rectal cancer?
 
15:59
Drs. Mario Dicato and Eric Van Cutsem, along with Dr. Josep Tabernero, chaired the ESMO 15th World Congress on Gastrointestinal Cancer which was held in Barcelona, Spain, 3-6 July 2013. This webcast includes most of the clinical presentations from this premier meeting. Didactic lectures, case studies, debates, and cutting-edge research from expert international faculty comprise the outstanding content of the World Congress. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Detail.aspx?activityid=6822 © 2013 Imedex, LLC.
Views: 787 ImedexCME
Imaging in rectal cancer: What is mandatory for optimal staging?
 
16:57
Drs. Mario Dicato and Eric Van Cutsem, along with Dr. Josep Tabernero, chaired the ESMO 15th World Congress on Gastrointestinal Cancer which was held in Barcelona, Spain, 3-6 July 2013. This webcast includes most of the clinical presentations from this premier meeting. Didactic lectures, case studies, debates, and cutting-edge research from expert international faculty comprise the outstanding content of the World Congress. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Detail.aspx?activityid=6822 © 2013 Imedex, LLC.
Views: 5154 ImedexCME
SIRFLOX Study in Colorectal Cancer
 
10:54
In this segment, David Liu, MD; Volker Heinemann, MD; and Marwan Fakih, MD, examine the use of radioembolization in individuals with advanced colorectal cancer with liver metastases.
Views: 234 OncLiveTV
Early- Versus Late-Onset Colorectal Cancer
 
06:37
In the opening segment to “The Biology of Extending Survival in Metastatic Colorectal Cancer,” John L. Marshall, MD; Dirk Arnold, MD, PhD; Fortunato Ciardiello, MD, PhD; Paul R. Helft, MD; and Tanios Bekaii-Saab, MD, provide insight into global trends in the prevalence of early-onset colorectal cancer and the potential impact on screening guidelines.
Views: 874 OncLiveTV
Laparoscopic Nerve Sparing Low Anterior Resection for the treatment of rectal cancer
 
18:41
Laparoscopic Nerve Sparing Low Anterior Resection for the treatment of rectal cancer
Views: 303 M Fatih Can
Debate 4: Appropriate Pre-op Therapy in Rectal Cancer - Short-course RT
 
10:56
Filmed on location in New York during the Great Debates and Updates in GI Malignancies 2015, this webcast is part of a series that provides educational discussions on controversial areas in the management of gastrointestinal malignancies. Join us as nationally-recognized thought leaders take opposing sides on topics of clinical interest, and present updates in standards of care. In this presentation, Dr. Christopher H. Crane argues for the use of short-course radiation as the optimal pre-op treatment for rectal cancer patients. © 2015 Imedex, LLC.
Views: 160 ImedexCME
Mesorectal Excision DVD #2 - Part 3: MRI of the Low Rectum
 
32:55
Mesorectal Excision DVD #2 - Part 3: MRI of the Low Rectum (EUR150049)
EMCCC 2010: Outcomes of clinical trials into colorectal radiotherapy treatments
 
05:42
Professor Gerard discusses recent clinical trials including the TME and CRO7 trials that have shown the importance of preoperative radiotherapy in reducing relapse rate and the STAR trial that has shown the benefits of combining of chemotherapy and radiotherapy, escalating the radiotherapy dose to 50 Gy and that capecitabine should be used without oxaliplatin when treating T3 and T4 tumours. Prof Jean-Pierre Gerard - Centre Antoine-Lacassagne, Nice
Views: 202 ecancer
Treatment of surgically resectable colorectal peritoneal metastases
 
19:41
This Congress is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors. It has been endorsed by leading professional societies and organizations. With the focus on personalized therapy, multidisciplinary management and unraveling molecular mechanisms, the World Congress will educate and update the broad range of experts who participate in the treatment of gastrointestinal cancers, providing a clear overview for treatment. In this presentation, Dr. Brendan J. Moran discusses the treatment of surgically-resectable colorectal peritoneal metastases. © 2015 Imedex, LLC.
Views: 302 ImedexCME
Immune therapy in non-colorectal GI cancer
 
19:19
In this presentation from the ESMO 19th World Congress on Gastrointestinal Cancer, Dr. Yelena Janjigian discusses the role of immune therapy in non-colorectal gastrointestinal cancers. Earn CME credit for related activities at http://elc.imedex.com © 2017 Imedex, LLC.
Views: 115 ImedexCME
Debate 4: Appropriate Pre-op Therapy in Rectal Cancer - Chemo alone
 
15:06
Filmed on location in New York during the Great Debates and Updates in GI Malignancies 2015, this webcast is part of a series that provides educational discussions on controversial areas in the management of gastrointestinal malignancies. Join us as nationally-recognized thought leaders take opposing sides on topics of clinical interest, and present updates in standards of care. In this presentation, Dr. Deborah Schrag argues for the use of chemotherapy alone as pre-op treatment for rectal cancer patients. © 2015 Imedex, LLC.
Views: 133 ImedexCME
Rectal Cancer
 
00:21
Multiple MR images demonstrate a mass arising along the right aspect of the rectum, with a large polyploid component, as well as extension involving the rectal wall from roughly the 9:00 to 12:00 positions. The mass does appear to demonstrate mesorectal involvement. This is a classic example of rectal cancer with mesorectal involvement. 16BMR2
Views: 381 CTisus
Dr. Melis on Avoiding Surgery for Patients With Rectal Cancer
 
01:51
Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.
Views: 310 OncLiveTV
Chemo-radiotherapy for the treatment of anal cancer (CORMAC)
 
03:06
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com, https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn , ,https://plus.google.com/u/0/+AlexandrosGSfakianakis , https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ , https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA , https://twitter.com/g_orl?lang=el, https://www.instagram.com/alexandrossfakianakis/, Systematic review of outcome measures following chemo-radiotherapy for the treatment of anal cancer (CORMAC). Colorectal Dis. 2018 Mar 22;: Authors: Fish R, Sanders C, Ryan N, Van der Veer S, Renehan AG, Williamson PR Abstract AIM: Six phase III randomised trials have determined the effectiveness of chemoradiotherapy as primary treatment for anal squamous cell carcinoma (ASCC), but outcomes reported in these trials varied widely, hindering evidence synthesis. To improve reporting in all future trials, we aim to develop a core set of outcomes (COS). As the first stage of COS development, we undertook a systematic review to summarise the outcomes reported in studies evaluating chemoradiotherapy for ASCC. METHOD: Systematic literature searches identified studies evaluating radiotherapy or chemoradiotherapy for ASCC. Outcomes and accompanying definitions were extracted verbatim and categorised into domains. RESULTS: From 5170 abstracts, we identified 95 eligible studies, reporting 1192 outcomes and 533 unique terms. We collapsed these terms into 86 standardised outcomes and five domains: survival; disease activity; life impact (including quality-of-life, QoL); delivery of care; and toxicity. The most commonly reported domains were survival and disease activity, reported in 74 (86%) and 54 (62%) studies, respectively. No outcome was reported in every publication. Over half (43/86) of the standardised outcome terms were reported in less than 5 studies, and 21 (25%) were reported in a single study only. There was wide variation in definitions of disease-free, colostomy-free, and progression-free survival (PFS). Anal continence was reported in only 35 (41%) studies. CONCLUSION: Outcomes reported in studies evaluating chemoradiotherapy for ASCC were heterogenous and definitions varied widely. Outcomes likely to be important to patients such as ano-rectal function, toxicity and QoL have been neglected. A COS for future trials will address these issues. This article is protected by copyright. All rights reserved. PMID: 29566456 [PubMed - as supplied by publisher]
Is tumor location relevant in the treatment decision in metastatic disease?
 
14:59
The ESMO World Congress on Gastrointestinal Cancer is the premier annual event in gastrointestinal cancer. At this year's meeting, experts from around the world convened in Barcelona, Spain from 29 June - 2 July 2016 to present, discuss, and debate the latest advances, treatment strategies, and guidelines for the treatment of gastrointestinal malignancies. In this presentation, Dr. Heinz-Josef Lenz discusses whether tumor location is relevant in the treatment decision in metastatic disease. © 2016 Imedex, LLC.
Views: 290 ImedexCME
How is Brachytherapy Used to Treat Colon Cancer?
 
01:50
Brachytherapy, or the treatment of cancer by the insertion of radioactive implants directly into the tissue, is generally only used in very specialized cases in colon cancer. Dr. Murty explains. Dr. Murty received his Doctor of Medicine degree from the University of Medicine and Dentistry - New Jersey Medical school. He completed his internship in internal medicine and residency in radiation oncology at Drexel University College of Medicine in Philadelphia where he served as Chief Resident. He has done research and published on the radiotherapeutic treatment of squamous cell carcinomas of the head and neck of unknown origin and total mesorectal excision of rectal cancers. His publications also include a book chapter on the radiation of vascular tumors of the ocular fundus. VIEW THE ARTICLE: http://www.coloncanceranswers.com/?p=12125 LAST WEEK'S VIDEO - Why are Genetics in Colon Cancer Important? - http://www.youtube.com/watch?v=Ee94e8rbN8I SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING COLON CANCER NEWS http://www.youtube.com/subscription_c... VISIT COLONCANCERANSWERS.com FOR TONS OF INFORMATIVE VIDEOS http://www.coloncanceranswers.com/ SUGGEST THE NEXT TOPIC FOR OUR COLON CANCER EXPERTS! http://www.coloncanceranswers.com/ CONNECT WITH US! Google+ : http://bit.ly/169ii4g Facebook : https://www.facebook.com/ColonCancerA... Twitter : https://twitter.com/ColonCancerQA
Robotic Esophagectomy Post Chemo & Radiation
 
09:53
This video from Consultant and Head of Thoracic Surgical Oncology at Rajiv Gandhi Cancer Institute and Research Centre, Dr. L. M. Darlong, shows robotic mobilization of the esophagus for squamous cell carcinoma following preoperative chemo-radiation. (Mckewan Esophagectomy) The procedure is done in the left lateral decubitus position. Three robotic arms are used along with a utility port for bedside assistance. The video of surgery is very crisp from the da Vinci robotic camera and is augmented with titles pointing at key anatomical points throughout. Not narrated, 09:52
CEA and CT May Be Useful to Detect Curable Colorectal Cancer Recurrence a New Study Finds
 
03:46
Please like, subscribe, comment and share! SUBSCRIBE: https://www.youtube.com/user/DrJohnKiel FACEBOOK: https://www.facebook.com/medicinelifestyle TWITTER: https://twitter.com/LifestyleMedYou A little background. Colon cancer is the third most common cancer in the world. Meta-analyses have suggested that CEA and CT are the only modes with significant potential to detect curatively treatable metastatic recurrence in patients with colorectal cancer. 5 year survival rates for metastasis have been improving and the likelihood of survival goes up if metastatic disease is treated before it becomes symptomatic. There are published studies outlining different monitoring strategies, but none that have compared CEA and CT to treatable recurrence on this scale. In conclusion, these results show that intensive follow-up by either scheduled CEA or CT increased the likelihood of detecting a recurrence that can be treated with curative intent. Combined CEA and CT was not superior to either individually. Because CEA testing can be done in primary care, it is likely to be more cost-effective than regular CT imaging. However, if there is an advantage to survival with either monitoring strategy, it is likely to be small.
Views: 4358 Lifestyle Medicine
Final Thoughts on Optimizing the Treatment of mCRC
 
05:42
Panelists provide their final thoughts on the next steps for the treatment of patients with colorectal cancer, which has evolved rapidly in the past 10 years. To view more from this discussion, visit http://www.onclive.com/peer-exchange/mcrc-optimization
Views: 263 OncLiveTV
Leiomyosarcoma of Inferior Vena Cava: Resection & Reconstruction (Links to Full Procedure)
 
01:00
Watch the FULL SURGICAL PROCEDURE at https://jomi.com/article/184 ABSTRACT: Primary leiomyosarcomas of the inferior vena cava (IVC) are rare tumors with complex anatomical relationships. Surgical resection remains the primary approach for management, with selective use of preoperative radiation and chemotherapy. Given the propensity for local invasion of these tumors, radical resection of surrounding structures is often required. Herein we describe the presentation, work-up, operative management, and outcomes of these lesions through the case of a patient with a tumor involving the middle segment of the IVC. Given the extent of involvement, IVC resection with en bloc right nephrectomy, right adrenalectomy, and partial left renal vein resection was performed with vascular reconstruction using a prosthetic graft. With appropriate preoperative planning and a well-coordinated multidisciplinary approach, aggressive surgical resection can be safely performed and patients can benefit from favorable long-term survival.
Week8 day 2
 
04:07
Week 8 of Cancer Treatment
Views: 62 Paul Scupham
Dr. Raghav on HER2 Amplification in Patients With CRC
 
01:57
Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer (mCRC).
Views: 126 OncLiveTV
Predictors of adherence to enhanced recovery pathway elements after colorectal surgery
 
09:04
Presented by Juan Mata at the SS05: Colorectal 1 held during the 2017 SAGES Annual Meeting in Houston, TX on Wednesday, March 22, 2017
Bowel Cancer UK's Colorectal Cancer Study Day 2017 - A patient's perspective
 
32:49
Listen to Deborah James talk about her experience being diagnosed with advanced bowel cancer and the impact it's had on her and her family. This was one of a number of talk throughout the day, aimed at healthcare professionals to understand more about colorectal cancer (bowel cancer) and how to improve a patient's experience. For more information about our the training and education we provide, please visit: https://www.bowelcanceruk.org.uk/for-health-professionals/training/
Views: 291 Bowel Cancer UK
EMCCC 2010: Total Mesorectal Excision
 
09:54
In response to the debate topic 'Partial mesorectal excision is adequate for rectal cancer', Prof Heald explains the procedure for a mesorectal excision procedure and describes how partial mesorectal excision is only appropriate when a tumour is in the upper third of the rectum. Prof Heald goes on to offer advice on key decisions that must be made by patients contemplating rectal surgery such as whether to opt for preoperative chemotherapy and radiotherapy or whether to have an anterior excision in which anal sphincter is preserved and highlights the risk of the surgery affecting sexual function. Prof Bill Heald OBE - Pelican Cancer Foundation, UK
Views: 1439 ecancer
IBD Case Presentation: Bridging the art and science of preventive care needs in IBD - Older Patient
 
15:55
In this presentation from the "Is Timing Everything? Making Vaccination-Related Preventive Care Decisions Early in IBD" symposium, Dr. Sunanda V. Kane discusses the case of 60 yr old with longstanding ileocolonic Crohn’s disease. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7297&specialty=Gastroenterology © 2018 Imedex, LLC.
Views: 112 ImedexCME
Overview of Late-Line Therapies for Metastatic Colorectal Cancer
 
11:00
In Part 1 of the 'Optimizing Dosing Strategy for Late-Line Therapies in mCRC' roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van Cutsem provide an overview of current standards of care for patients with relapsed/refractory metastatic colorectal cancer. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7287 © 2018 Imedex, LLC.
Views: 106 ImedexCME
How Common is Relapse after Surgery for Colon Cancer? - Ovunc Bardakcioglu, MD
 
00:29
The odds of relapse after colon surgery for cancer depends on the staging, says Ovunc Bardakcioglu, MD, a colon and rectal surgeon at Sunrise Hospital. In this video, he explains what treatments follow surgery, based on staging. Visit our website for more information: http://sunrisehospital.com/
Debate: Does radiation therapy play a role in gastric cancer adjuvant therapy? - Yes
 
08:19
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that post-operative radition therapy is required in this setting. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GDUGI © 2017 Imedex, LLC.
Views: 167 ImedexCME
Grand Rounds Presentation on Curing Rectal Cancer
 
53:18
Gastrointestinal Oncology Service Chief Leonard Saltz talks about advances in the personalized treatment and cure of rectal cancer in this Grand Rounds presentation.
Neoadjuvant and Adjuvant Therapy in Metastatic Colorectal Cancer
 
05:07
Panelists John L. Marshall, MD; Tanios Bekaii-Saab, MD; Cathy Eng, MD; Daniel G. Haller, MD; and Tara E. Seery, MD provide insight on the rationale for neoadjuvant and adjuvant therapy in metastatic colorectal cancer.
Views: 43 OncLiveTV
The Impact of HER2 Amplification in Colorectal Cancer
 
02:23
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 107 Targeted Oncology
Screening in familial and hereditary pancreatic cancer
 
18:34
In this presentation from the ESMO 19th World Congress on Gastrointestinal Cancer, Dr. Margaret A. Tempero discusses screening in familial and hereditary pancreatic cancer. Earn CME credit for related activities at http://elc.imedex.com © 2017 Imedex, LLC.
Views: 503 ImedexCME
Is CT/RT Still Standard Treatment for all Clinically Staged II and III Rectal Cancer?
 
03:05
AIS CHANNEL INFO: This is a trailer video, watch the full version free here: http://aischannel.com/?p=292 VIDEO DESCRIPTION: Preoperative chemoradiation (CT/RT) followed by surgery has been the standard of care in USA/Europe for all patients with clinical stage II and III rectal cancer. New advances to adapt our behavior.
Views: 51 AIS Channel
The GI oncologist of the future
 
10:32
In this presentation from the ESMO 19th World Congress on Gastrointestinal Cancer, Dr. Axel Grothey discusses the future of GI oncology and the role of the GI oncologist in the future. Earn CME credit for related activities at http://elc.imedex.com © 2017 Imedex, LLC.
Views: 92 ImedexCME
How to Maintain Nutrition During Cancer
 
01:15
Our free newsletter is here! http://www.ihealthtube.com/content/newsletter Dr. Kevin Conners addresses the challenge of getting the proper nutrition during cancer treatment. Often, many of those treatments leave the patient not willing or able to eat much or anything at all!
Views: 1633 iHealthTube.com
Q&A with Douglas Faigel: Starting to Win The War on Colon Cancer
 
04:10
Douglas Faigel, Md, FACG, FASGE, Mayo Clinic, Arizona, and President of ASGE, spoke at the 2015 American College of Gastroenterology Annual Scientific Meeting very crucial and hot topics he and his colleagues discussed with the CMS early Monday morning. Faigel said, "We're starting to win the war on colon cancer and the last thing we want to do is put up barriers for patient Medicare beneficiary access to colonoscopies."
Views: 78 MD Magazine
CEA
 
07:44
CEA
Monitoring colorectal cancer and selected other cancers such as medullary thyroid carcinoma  May be useful in assessing the effectiveness of chemotherapy or radiation treatment  Carcinoembryonic antigen levels are not useful in screening the general population for undetected cancers. News Theme 1 by Audionautix is licensed under a Creative Commons Attribution licence.
Views: 1102 Sachin Kale
Low anterior resection for rectum cancer. Operated by Dr. Tariq Akhtar Khan
 
00:13
This was done for a cancer of lower rectum 5 cm away from anal verge. For this previously APR with permanent end colostomy was the only option. Now with the use of these staplers we can preserve the anus without compromising the oncological clearance.
Views: 304 Tariq Khan